118 Ways to Improve Clinical IHC Staining

Leica Microsystems continues to make high-quality IHC more efficient with the release of eight
important new antibodies in the Bond ready-to-use (RTU) format.

New antibodies:

• Beta-Catenin (clone 17C2)

• Cytokeratin 17 (clone E3)
• Gastrin (polyclonal)
• Galectin-3 (clone 9C4)
• Ki67 (clone K2)
• MLH1 (Mismatch Repair Protein) (clone ES05)
• Multiple Myeloma Oncogene 1 (MUM1) (clone EAU32)
• Tartrate-Resistance Acid Phosphatase (clone 26E5)

Leica Microsystems has selected each new product for superior performance and clinical
relevance. A highlight of this release is the new K2 clone for Ki67. This new clone has shown
exceptional results during development and is now recommended as the preferred Ki67 clone (the
older MM1 clone will continue to be available).

Another antibody of great interest is MLH1 which helps identify individuals predisposed for hereditary
non-polyposis colorectal cancer. Tartrate-Resistance Acid Phosphatase (often used in panels for
identifying hairy cell leukemia) and Multiple Myeloma Oncogene 1 (useful in panels for the
identification or characterization of B cell and Hodgkin’s lymphoma) will also quickly find use as
diagnostic aids.

The launch of these new products expands the range of Bond ready-to-use antibodies to 118
worldwide (117 in the USA). All antibodies (including the new releases) are now available from Leica
Microsystems or an authorized Bond system distributor in each region.

Renowned for being the easiest way to consistently produce diagnostic-quality IHC slides, the Bond
RTU format replaces dilution, titration and mixing with a simple 4-step process:

1. Load – place a registered container on Bond

2. Select – choose the antibody and an optimized protocol is automatically selected
3. Run – just press start and walk away
4. Review – enjoy consistent, high-quality results

You may like to see diagnostic equipment, diagnostic instruments, clinical diagnostics companies to visit
our website www.leicabiosystems.com